Advertisement

World Journal of Surgery

, Volume 41, Issue 5, pp 1347–1357 | Cite as

Post-resection Prognosis of Combined Hepatocellular Carcinoma-Cholangiocarcinoma According to the 2010 WHO Classification

  • Dong-Hwan Jung
  • Shin HwangEmail author
  • Seung-Mo Hong
  • Yong-Kyu Chung
  • Gi-Won Song
  • Young-Joo Lee
  • Ki-Hun Kim
  • Chul-Soo Ahn
  • Deok-Bog Moon
  • Tae-Yong Ha
  • Gil-Chun Park
  • Han Chu Lee
  • Young-Suk Lim
  • Eun Sil Yu
  • Sung-Gyu Lee
Original Scientific Report

Abstract

Background

Combined hepatocellular carcinoma and cholangiocarcinoma (cHC) has wide histological diversity. We intended to investigate the prognostic influence of tumor types of cHC.

Methods

We analyzed the clinical and pathological features of cHC along 2010 WHO classification. Study group was 100 cHC patients who underwent primary resection. Control group comprised 200 propensity score-matched patients with intrahepatic cholangiocarcinoma (ICC).

Results

In cHC group, tumor diameter was 4.4 ± 2.8 cm and 95 patients had single tumor. They were classified as classical type in 46 and subtypes with stem cell (SC) features in 54. Subtypes with SC features included typical in 16, intermediate cell in 22, and cholangiolocellular in 16. Their 1- and 3-year tumor recurrence rates were 31.7 and 59.8%; and 1- and 3-year patient survival rates were 92.5 and 77.3%, respectively. Tumor recurrence (p = 0.008) and patient survival (p = 0.005) rates were different according to tumor types. Further stratification by subtypes with SC features resulted in prognostic stratification in tumor recurrence (p = 0.045) and patient survival (p = 0.042). However, tumor stage was the only independent risk factor for tumor recurrence and patient survival. Comparing with ICC control group, cHC group showed no significant difference in rates of tumor recurrence (p = 0.523), but better survival outcomes (p = 0.008). Median post-recurrence patient survival period was 20 months in cHC patients and 6 months in ICC patients (p = 0.001).

Conclusions

Our results indicated that there would be close relationship between the post-resection prognosis and histological types according to the 2010 WHO classification, but these histological types did not become an independent prognostic factor.

Keywords

Classical Type Patient Survival Rate Stem Cell Feature Tumor Recurrence Rate Good Survival Outcome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (Grant Nos. 2015R1A2A2A04007141 and 2015K1A4A3046807).

Compliance with ethical standards

Conflict of interest

There were no authors who have conflict of interest to disclose.

Author contributions

HS and JDH designed the study; HSM, SGW, LYJ, KKH, ACS, MDB, YES, HTY, PGC, LHC, LYS, and LSG contributed to data acquisition and statistical analysis; and HS and JDH drafted and revised the article. All authors approved the submitted version of manuscript.

References

  1. 1.
    Allen RA, Lisa JR (1949) Combined liver cell and bile duct carcinoma. Am J Pathol 25:647–655PubMedPubMedCentralGoogle Scholar
  2. 2.
    Goodman ZD, Ishak KG, Langloss JM et al (1985) Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 55:124–135CrossRefPubMedGoogle Scholar
  3. 3.
    Theise ND, Park YN, Nakanuma Y (2010) Combined hepatocellular-cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumours of the digestive system, 4th edn. IARC, Lyon, pp 225–227Google Scholar
  4. 4.
    Yoon YI, Hwang S, Lee YJ et al (2016) Postresection outcomes of combined hepatocellular carcinoma-cholangiocarcinoma, hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Gastrointest Surg 20:411–420CrossRefPubMedGoogle Scholar
  5. 5.
    Ikeda H, Harada K, Sato Y et al (2013) Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers. Am J Clin Pathol 140:329–340CrossRefPubMedGoogle Scholar
  6. 6.
    Akiba J, Nakashima O, Hattori S et al (2013) Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 37:496–505CrossRefPubMedGoogle Scholar
  7. 7.
    Sasaki M, Sato H, Kakuda Y et al (2015) Clinicopathological significance of ‘subtypes with stem-cell feature’ in combined hepatocellular-cholangiocarcinoma. Liver Int 35:1024–1035CrossRefPubMedGoogle Scholar
  8. 8.
    Cho HD, Hwang S, Lee YJ et al (2016) Changes in the types of liver diseases requiring hepatic resection: a single-institution experience of 9016 cases over a 10-year period. Korean J Hepatobiliary Pancreat Surg 20:49–52CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Hwang S, Ha TY, Song GW et al (2015) Quantified risk assessment for major hepatectomy via the indocyanine green clearance rate and liver volumetry combined with standard liver volume. J Gastrointest Surg 19:1305–1314CrossRefPubMedGoogle Scholar
  10. 10.
    Hwang S, Lee YJ, Kim KH et al (2015) The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: single-institution experience with 2558 patients. J Gastrointest Surg 19:1281–1290CrossRefPubMedGoogle Scholar
  11. 11.
    The Korean Association for the Study of the Liver (KASL) (2016) KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 22:18–75CrossRefGoogle Scholar
  12. 12.
    Hwang S, Lee YJ, Song GW et al (2015) Prognostic impact of tumor growth type on 7th AJCC staging system for intrahepatic cholangiocarcinoma: a single-center experience of 659 cases. J Gastrointest Surg 19:1291–1304CrossRefPubMedGoogle Scholar
  13. 13.
    Kim JH, Yoon HK, Ko GY et al (2010) Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology 255:270–277CrossRefPubMedGoogle Scholar
  14. 14.
    Chantajitr S, Wilasrusmee C, Lertsitichai P et al (2006) Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg 13:537–542CrossRefPubMedGoogle Scholar
  15. 15.
    Lee JH, Chung GE, Yu SJ et al (2011) Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol 45:69–75PubMedGoogle Scholar
  16. 16.
    Tang D, Nagano H, Nakamura M et al (2006) Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg 10:987–998CrossRefPubMedGoogle Scholar
  17. 17.
    Garancini M, Goffredo P, Pagni F et al (2014) Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transplant 20:952–959CrossRefGoogle Scholar
  18. 18.
    Kojiro M (1992) Pathomorphology of advanced hepatocellular carcinoma. In: Tobe T, Kameda H, Okudaira M et al (eds) Primary liver cancer in Japan. Springer, TokyoGoogle Scholar
  19. 19.
    Shiraishi M, Takushi Y, Simoji H et al (1998) Combined hepatocellular and cholangiocellular carcinoma in a non-cirrhotic liver. J Gastroenterol 33:593–596CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang F, Chen XP, Zhang W et al (2008) Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology 52:224–232CrossRefPubMedGoogle Scholar
  21. 21.
    Kim H, Park C, Han KH et al (2004) Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 40:298–304CrossRefPubMedGoogle Scholar
  22. 22.
    Ariizumi S, Kotera Y, Katagiri S et al (2014) Long-term survival of patients with cholangiolocellular carcinoma after curative hepatectomy. Ann Surg Oncol 21(Suppl 3):S451–S458CrossRefPubMedGoogle Scholar
  23. 23.
    Lee CH, Hsieh SY, Chang CJ et al (2013) Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers. J Gastroenterol Hepatol 28:122–127CrossRefPubMedGoogle Scholar
  24. 24.
    Fowler K, Saad NE, Brunt E et al (2015) Biphenotypic primary liver carcinomas: assessing outcomes of hepatic directed therapy. Ann Surg Oncol 22:4130–4137CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2016

Authors and Affiliations

  • Dong-Hwan Jung
    • 1
  • Shin Hwang
    • 1
    Email author
  • Seung-Mo Hong
    • 2
  • Yong-Kyu Chung
    • 1
  • Gi-Won Song
    • 1
  • Young-Joo Lee
    • 1
  • Ki-Hun Kim
    • 1
  • Chul-Soo Ahn
    • 1
  • Deok-Bog Moon
    • 1
  • Tae-Yong Ha
    • 1
  • Gil-Chun Park
    • 1
  • Han Chu Lee
    • 3
  • Young-Suk Lim
    • 3
  • Eun Sil Yu
    • 2
  • Sung-Gyu Lee
    • 1
  1. 1.Department of Surgery, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea
  2. 2.Department of Pathology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea
  3. 3.Department of Internal Medicine, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea

Personalised recommendations